Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4090 - Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Immunotherapy

Tumour Site

Breast Cancer

Presenters

Benedetta Conte

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

B. Conte1, A. Fabi2, F. Poggio3, E. Blondeaux1, C. Dellepiane1, A. D'Alonzo1, A. Staiano1, G. Buono4, G. Arpino4, V. Magri5, G. Naso6, D. Presti7, S. Mura8, A. Fontana9, F. Cognetti2, C. Molinelli1, S. Pastorino1, C. Bighin1, M. Lambertini3, L. Del Mastro1

Author affiliations

  • 1 Medical Oncology, Ospedale Policlinico San Martino, 16132 - Genova/IT
  • 2 Medical Oncology, Istituto Nazionale Tumori Regina Elena, 144 - Rome/IT
  • 3 Medical Oncology, Institut Jules Bordet, L’Université Libre de Bruxelles, Brussels/BE
  • 4 Medical Oncology, AOU Policlinico Federico II, 80131 - Napoli/IT
  • 5 Medical Oncology, Policlinico Umberto I, 00161 - Rome/IT
  • 6 Medical Oncology, Policlinico Umberto I, 161 - Rome/IT
  • 7 Medical Oncology, Istituto Fondazione Maugeri, Pavia/IT
  • 8 Medical Oncology, Ospedale Santissima Annunziata, Sassari/IT
  • 9 Medical Oncology, Azienda Ospedaliera Universitaria Pisana, 56100 - Pisa/IT
More

Resources

Abstract 4090

Background

In patients with HER2-positive ABC who were previously treated with taxane and trastuzumab without pertuzumab, TDM1 showed a progression free survival (PFS) of 9.6 months and an overall survival (OS) of 29.9 months. Paucity of data is available on the efficacy of TDM1 in patients progressing after the current standard first-line therapy in this setting, based on the association of a taxane plus trastuzumab and pertuzumab (i.e. the TPH regimen). The present study aims to evaluate the effectiveness of TDM1 after first-line TPH.

Methods

The Gruppo Italiano Mammella (GIM) 14/BIOMETA is a retrospective/prospective multicenter study on treatment patterns and outcomes of patients with ABC. The present analysis was performed on patients who received second-line TDM1 after previous TPH between January 2012 and March 2017. Median PFS, 1-year OS (i.e. percentage of patients alive 1 year after the starting of TDM1) and clinical benefit rate (CB) were calculated. Descriptive statistics are reported with point estimated and 95% CIs. PFS was estimated with the Kaplan-Meier method.

Results

Out of 1858 patients included in the GIM14/BIOMETA study, 70 were eligible for the present analysis. Median age was 54 years; 36 patients (51%) had hormone receptor-positive/HER2-positive disease, and 27 (39%) had visceral involvement. All patients received TPH in the first-line setting, and 35 (50%) received taxane and trastuzumab in the adjuvant setting. At the time of data cutoff (April 30, 2018; median duration of follow-up 17.8 months), 30 patients (43%) were still receiving TDM1. Disease progression was the reason for treatment discontinuation in the remaining cases. Median PFS was 8.5 months (95% confidence intervals [CI] 5.3-12 months), and CB rate was 73%. One-year survival rate was 91%.

Conclusions

Our findings suggest that TDM1 is effective in patients progressing after TPH. A better performance was observed as compared to data previously published on TDM1 effectiveness after first-line TPH.

Clinical trial identification

NCT02284581.

Legal entity responsible for the study

Consorzio Oncotech.

Funding

Roche.

Editorial Acknowledgement

Disclosure

L. Del Mastro: Honoraria: Ipsen, Roche, Pfizer, Novartis, Eli Lilly, Eisai. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.